GVHD, Chronic Clinical Trial
Official title:
Improvement of Women's Health After Allogeneic Stem Cell Transplantation
The aim of this prospective research project is to better understand vulvovaginal cGVHD to improve care of allografted women. The expected outcomes include better knowledge of the incidence and manifestations of vulvovaginal cGVHD, risk factors, response to treatments and impact on sexual health of allotransplanted female patients. The knowledge acquired will allow transplant clinicians to make more precise recommendations for gynecological management of future allografted women.
The invetigators plan to recruit 100 women who will be evaluated 9 times over a period of 2 years (before allograft, at + 3 months, +6 months, +9 months, +12 months, +15 months, +18 months, +21 months, and +24 months +/- 14 days). If a new diagnosis of cGVHD is made between 2 visits, an additional gynecological examination will be performed. Visits by the Hôpital Maisonneuve-Rosemont Hospital transplant team will include a physical examination to assess for the presence of cGVHD using the NIH criteria. The FACT-BMT quality of life questionnaire will also be completed before the allograft, at 3 months and 6 months after transplant. If cGVHD is diagnosed, the participants will also have to complete two questionnaires specific to cGVHD (Lee Scale for cGVHD, Patient self-assessment of cGVHD) at diagnosis and then at + 6, +12, +18 and +24 months from day 0 of allograft. Assessments by CHUM gynecologists will take place before the allograft, then at +3, +6, +12, +18 and +24 months from day 0 of the allograft and will include: a vulvar/vaginal examination, a sample for HPV testing and sexual health questionnaires to be completed (Personal assessment of intimacy within relationships - PAIR, Female Sexual Function Index - FSFI , Female Sexual Distress Scale-Revised - FSDS-R). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03042676 -
Electronic Database for the Follow up of the ATG_FamilyStudy
|
||
Recruiting |
NCT05401955 -
Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD)
|
N/A | |
Recruiting |
NCT04932564 -
Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant
|
Phase 2 | |
Not yet recruiting |
NCT06169722 -
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
|
Phase 1/Phase 2 | |
Terminated |
NCT04107675 -
A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)
|
Phase 2 | |
Recruiting |
NCT06462365 -
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
|
Phase 1 | |
Completed |
NCT04884204 -
Systematic Symptom Identification With Disease Specific PROM to Assess Symptoms of Chronic GVHD in Outpatient Care in Patients Post HSCT
|
N/A | |
Completed |
NCT04930562 -
Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)
|
Phase 2 |